Abstract

Mood disorders are of public health concern and non-adherence to medication seems to be a major issue in mood disorders such as bipolar. A plethora of pharmacological treatment intervention exist for mood disorder but their universal effectiveness have not been achieved especially because some of the treatments are associated with uncomfortable side effects which affect treatment, particularly medication adherence. A review of the emerging or investigational pharmaceutical treatment for bipolar disorder was conducted. The pharmacokinetic and pharmacodynamic of first generation long-acting injectable antipsychotic such as Flupentixole Decanoate was reviewed. The paper reviewed several researches and discourses on the use of mobile technology as a viable option for improving medication adherence among patients with mood disorders. The Benefits of use of mobile technology for medication adherence in mood disorders was discussed and the challenges with the use of mobile technology for medication adherence in mood disorders were also reviewed. Consequently, the gaps yet to be understood with the use of mobile technology for medications adherence in mood disorders was identified. The review concludes that long acting injectables has the potential to be used for treating all stages of depression and agitations which mainly characterize bipolar experiences. It is further concluded that there are prospects with the use of mobile technology in the improvement of medication adherence among mood disorder patients.

PDF